EVR 6.7MSFT 0.71DAL 0.73JPM 10.04ATD.TO 0.76MTD 11.16CRWD -28.52
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

25.69
+0.35 (1.38%)
as of Jun 4, 2026, 8:00:00 pm Market Open.
579 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconJun 4, 2026, 12:00 am

This summary was created by AI, based on 31 opinions in the last 12 months.

Pfizer Inc. (PFE) is currently facing significant challenges, primarily due to a patent cliff and a lack of earnings momentum following the COVID-19 pandemic. Many experts express concerns over its drug pipeline, indicating that the company is in need of a blockbuster drug to drive future growth. While it maintains an attractive dividend yield—ranging from 6.4% to 7%—there is skepticism about the sustainability of this yield if new profitable drugs are not developed soon. The stock’s valuation is seen as low, trading at around 8-10 times earnings, which some experts believe might make it appealing for patient investors. However, the consensus also points to caution due to the industry-wide challenges, including cost-cutting measures and potential government pressure on drug pricing.

consensus icon
Consensus
Hold
valuation icon
Valuation
Undervalued
review icon
Similar
NVO
COMMENT

Pfizer Inc(PFE)

May 16, 2007
Is preforming quite well without a lot of fanfare. Thinks it is going to trade to a discount, would rather go to a Sheering or Abbot.
Photo of David BurrowsDavid BurrowsUnlock Rating
$27.32

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

May 02, 2007
Hasn't moved but has the most value of similar stocks. Massively mispriced.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$26.60

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
COMMENT

Pfizer Inc(PFE)

May 01, 2007
Blue chip. Nice dividend. Don't expect too much excitement.
Photo of Michael SmedleyMichael SmedleyUnlock Rating
$26.59

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

May 01, 2007
(A Top Pick May 9/06. Up 4.2%.) Yield gave him another 4%. Sold their consumers products division for $19 billion so have a huge amount of cash on the books. Can't see a lot of downside here.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$26.59

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Apr 26, 2007
Has value characteristics which is positive, but he can't get comfortable with their largest drug Lipidor going off patent in 2011. Does not all they'll make up for this.
Photo of Pat NaccaratoPat Naccarato
No
Unlock Rating
$26.72

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Apr 16, 2007
His value drug play. Growth drug play is Teva Pharmaceutical (TEVA-Q). Pharmaceuticals got the wind kicked out of them a couple of years ago and are now showing some rebound. Very nice yield. Huge cash hoard and are buying back stock and probably will increase dividends again.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$26.94

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
BUY ON WEAKNESS

Pfizer Inc(PFE)

Apr 16, 2007
Looks like it is in the process of breaking the downtrend. That was established with the recent higher lows. If you own, he would Hold.
Photo of John ManleyJohn ManleyUnlock Rating
$26.94

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Apr 12, 2007
(A Top Pick May 10/06. Up 5.3%.) One of the cheapest stocks on the S&P500. His model price is $40.47 giving it a 55% positive differential. Any positive catalyst will help the stock price. Dividends are almost 5%.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$26.46

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Mar 28, 2007
The drug stocks in the US have been beat up. The problems they had have gotten somewhat better. Increased their dividend and are investing in more R&D. Buying back shares. Low multiple.
Photo of Norman LevineNorman LevineUnlock Rating
$25.18

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Mar 22, 2007
Doesn't like many of the big pharmaceuticals. Has a great deal of revenue at risk with Lipitor coming off patent and they don't have a lot to replace it.
Photo of Brad WillockBrad Willock
No
Unlock Rating
$25.79

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Mar 13, 2007
(A Top Pick Dec 5/06. Up to .3%.) Still has lots of upside and it has a good yield. Have a lot of cash.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$24.94

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Mar 08, 2007
(A Top Pick Dec 21/06. Down 2.5%.) Sold their consumer business. There is so much value there. New management is cutting costs. 4.7% dividend. Still likes.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$25.41

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Feb 12, 2007
Pays a nice dividend. Have tons of cash through their normal cash generation as well as selling their consumers product division. Using some of it to increase dividends and some to buy back shares. 13 X earnings.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$26.22

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Feb 01, 2007
This is a balance sheet story. They have a huge balance sheet that they can’t do anything with. Volatility in the stock price has fallen. New management wants to fire 10,000 people, etc. and it sounds like he wants to reduce the balance sheet. A restructuring story. 5% dividend. His current model price is $40, a 51% positive differential.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$26.62

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Jan 25, 2007
Drug companies have been struggling under generic competition as well as a difficult regulatory environment. Looks like compelling value here but would be more comfortable at $24.
Photo of John O'Connell, CFAJohn O'Connell, CFAUnlock Rating
$26.36

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
Showing 571 to 585 of 883 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

RY.TO 5.13$270.94
BHP -2.07$88.78
TA.TO -2.08$18
V 7.78$320.18
TOU.TO -0.12$65.42

Today's Top Picks

EVR 6.7$346.79
MSFT 0.71$428.05
DAL 0.73$79.51
JPM 10.04$310.89
ATD.TO 0.76$80.79

Popular Articles

Latest Sell Signals

PRL.TO 0.07$21.2
CNQ.TO -0.14$66.22
SHOP.TO 4.46$161.54
RIO -2.46$105.4
BB.TO 0.3$14.4

Most Recent Experts

The Panic-Proof Portfolio (Stockchase Research)

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Darren Sissons

Darren Sissons

Campbell Lee & Ross

The Weekly Buzzing Stocks by Billy Kawasaki

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

Joe Terranova

Joe Terranova

Virtus Investment Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica